Incyte Corporation (LON:0J9P)
74.41
-1.70 (-2.23%)
At close: Aug 1, 2025
Paragon 28 Revenue
Incyte had revenue of $1.22B USD in the quarter ending June 30, 2025, with 16.46% growth. This brings the company's revenue in the last twelve months to $4.58B, up 18.87% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.58B
Revenue Growth
+18.87%
P/S Ratio
3.33
Revenue / Employee
$1.75M
Employees
2,617
Market Cap
11.14B
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Incyte News
- 3 days ago - Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil - GlobeNewsWire
- 5 days ago - Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Incyte Corporation 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 days ago - Incyte rises on results beat, lifted Jakafi guidance - Seeking Alpha
- 5 days ago - Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga
- 5 days ago - Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga
- 5 days ago - Incyte lifts annual sales forecast for blood cancer drug after solid quarter - Reuters
- 5 days ago - Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Business Wire